Keywords
autonomic dysfunction
cardiac autonomic neuropathy
questionnaire
How to Cite
Abstract
Abstract. Cardiac autonomic neuropathy (CAN) in type 2 diabetes mellitus (T2DM) is considered as an independent risk factor for cardiovascular
mortality. Given the impact of CAN on the quality of life of patients with T2DM, it is recommended to assess the symptoms of autonomic dysfunction in each patient with diabetes. The «golden» standard in the diagnosis of CAN is based on the results of cardiovascular autonomic reflex tests (CART’s), but their implementation requires special equipment and mastery of techniques.
The aim is to assess the diagnostic information content of the Ukrainian-language version of the Composite Autonomic Symptom Score 31 (COMPASS 31) questionnaire, as a screening test for confirming autonomic dysfunction in patients with T2DM.
Material and methods. This is a cross-sectional study involving 32 people, 16 of whom were patients with T2DM and clinical CAN (main group) and 16 were practically healthy (control group). CAN was diagnosed in the presence of at least two abnormal tests. Age and gender of the examined subjects did not differ (p>0.05). CAN was verified using CART’s. CAN was diagnosed in the presence of at least two disturbed tests. The linguistically validated Ukrainian version of COMPASS 31 was translated using the forward/backward translation method. The COMPASS 31 consists of 31 questions grouped into six domains. The weighted scores for individual groups were summed to form a total weighted score (TWS). The TWS value which exceeded 16.44 was considered violated. Statistics: SPSS, IBM SPSS Statistics 20.
Results. It was found that patients with T2DM and clinical CAN had significantly higher TWS scores on the COMPASS 31 scale compared to the control group (21.8±9.4 vs. 11.2±9.1; p<0.05). The greatest contribution to the increase in TWS indices in patients with CAN belongs to the secretomotor (6.4±1.6 vs. 1.3±1.1; p<0.05) and gastrointestinal domains (6.0±1.3 vs. 1.8±1.0; p<0.05).
Conclusions. The use of the COMPASS 31 questionnaire is an acceptable tool for screening, particularly for identifying patients with
autonomic dysfunction.
References
Williams S, Raheim SA, Khan MI, Rubab U, Kanagala P, Zhao SS, et al. Cardiac autonomic neuropathy in type 1 and 2 diabetes: epidemiology, pathophysiology, and management. Clin Ther. 2022 Oct;44(10):1394-1416. doi: 10.1016/j.clinthera.2022.09.002.
Serhiyenko VA, Serhiyenko AA. The diabetes textbook: clinical principles, patient management and public health issues. 2nd ed. Basel: Springer, Cham. Springer Nature Switzerland AG; 2023. Chapter 57, Diabetic cardiac autonomic neuropathy; p. 939-966. doi:10.1007/978-3-031-25519-9_57.
Sletten DM, Suarez GA, Low PA, Mandrekar J, Singer W. COMPASS 31: a refined and abbreviated Composite Autonomic Symptom Score. Mayo Clin Proc. 2012 Dec;87(12):1196-1201. doi: 10.1016/j.mayocp.2012.10.013.
Greco C, Di Gennaro F, D’Amato C, Morganti R, Corradini D, Sun A, et al. Validation of the Composite Autonomic Symptom Score 31 (COMPASS 31) for the assessment of symptoms of autonomic neuropathy in people with diabetes. Diabet Med. 2017 Jun;34(6):834-838. doi: 10.1111/dme.13310.
Zhang Z, Ma Y, Fu L, Li L, Liu J, Peng H, et al. Combination of Composite Autonomic Symptom Score 31 and heart rate variability for diagnosis of cardiovascular autonomic neuropathy in people with type 2 diabetes. J Diabetes Res. 2020 Oct 30;2020:5316769. doi: 10.1155/2020/5316769.
Aguilar M, Alberti KGMM, Amiel SA, Azzopachi J, Berne C, Bilous RW, et al. Leitfaden zu typ-2-diabetes mellitus / Guide for type 2 diabetes mellitus (Review). Diabetes und Stoffwechsel. 2000 Mar 20;9(2):104-136. ISSN: 09420037.
Spallone V. Update on the impact, diagnosis and management of cardiovascular autonomic neuropathy in diabetes: what is defined, what is new, and what is unmet. Diabetes Metab J. 2019 Feb;43(1):3-30. doi: 10.4093/dmj.2018.0259.
Atala YB, De Matos MR, Zantut-Wittmann DE, Castillo AR, Santos-Bezerra DP, Correa-Giannella ML, et al. Cardiovascular autonomic reflex tests and 7 heart rate variability indices for early diagnosis of cardiovascular autonomic neuropathy in type 2 diabetes individuals. Curr Diabetes Rev. 2022;18(4):e270821195908. doi: 10.2174/1573399817666210827130339.
Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic neuropathy: A position statement by the American Diabetes Association. Diabetes Care. 2017 Jan;40(1):136-154. doi: 10.2337/dc16-2042.
Singh R, Arbaz M, Rai NK, Joshi R. Diagnostic accuracy of composite autonomic symptom scale 31 (COMPASS-31) in early detection of autonomic dysfunction in type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2019 Sep 5;12:1735-1742. doi: 10.2147/DMSO.S214085.
Meling S, Tjora E, Eichele H, Ejskjaer N, Carlsen S, Njølstad PR, et al. The Composite Autonomic Symptom Score 31 questionnaire: a sensitive test to detect risk for autonomic neuropathy. J Diabetes Res. 2023 Aug 9;2023:4441115. doi: 10.1155/2023/4441115.
Pierangeli G, Turrini A, Giannini G, Del Sorbo F, Calandra-Buonaura G, Guaraldi P, et al. Translation and linguistic validation of the Composite Autonomic Symptom Score COMPASS 31. Neurol Sci. 2015 Oct;36(10):1897-902. doi: 10.1007/s10072-015-2278-y.